NOTICE: We are continuing to provide all of our genetic testing during the COVID-19 pandemic, but the reporting times for some of our tests may be slower than usual. This delay could be due to three reasons:
laboratory resources being directed to testing for COVID-19
fewer interstate flights for shipping samples
a backlog of tests as restrictions on elective surgery and procedures are lifted
We apologise for any delay in reporting your genetic test result.
If you have any concerns about this, please speak with the doctor who ordered your genetic test.
Also known as: Pulmonary veno-occlusive disease, hereditary haemorrhagic telangiectasia, Osler–Weber–Rendu disease
Familial - Cardiac
Use of test
Pulmonary hypertension can be caused by abnormalities of cardiac structure or function, of lung parenchyma, or of the pulmonary vasculature.
Within these groups of disorders, there are some autosomal dominant and autosomal recessive conditions which can be caused by heritable mutations in a single gene. Mutations in such genes may cause multi-system disease, allowing a clinical diagnosis to be made. In some patients, the same mutations can cause isolated pulmonary hypertension without any clinical or radiological evidence to indicate which gene is involved.
Familial disorders which can cause isolated pulmonary hypertension include primary pulmonary arterial hypertension, pulmonary veno-occlusive disease (PVOD), and hereditary haemorrhagic telangiectasia (HHT).
The diagnosis of pulmonary hypertension is made on the basis of clinical history and electrocardiographic findings. Genetic testing is not necessary to make this diagnosis.
This test result has implications regarding the aetiology and inheritance of pulmonary hypertension in an individual, and the risk of pulmonary hypertension syndrome and related disorders in a patient's relatives. The interpretation of the result may be dependent on the family history and the interpretation of other studies.
A pathogenic mutation can be found in approximately 80-90% of patients with familial pulmonary arterial hypertension, pulmonary veno-occlusive disease, or hereditary haemorrhagic telangiectasia.
In an affected person, the presence of a pathogenic mutation confirms the diagnosis and may provide additional information regarding the risk of cardiac and non-cardiac manifestations in relatives. However, the absence of a pathogenic mutation in such a patient does not exclude the diagnosis of familial pulmonary hypertension.
In an unaffected person from a family with confirmed genetic diagnosis of familial pulmonary hypertension, the presence of the family's mutation may indicate an increased risk of developing pulmonary hypertension, and close clinical follow-up may be warranted. The interpretation of such results depends on the particular gene and mutations. Pre-test genetic counselling is strongly recommended.
This is an assay for heritable mutations. It may raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient. Pre-test genetic counselling and written consent are required, and are provided through Sonic Genetics at no additional cost (see Cardiac genetic counselling for details).
This test can assist in making a diagnosis in an affected patient. It may also provide useful risk information for unaffected relatives. Testing unaffected people to provide risk information may require that the clinician comply with guidelines provided by professional and regulatory authorities regarding pre-test counselling and consent. In particular, national regulations stipulate that carrier testing of an unaffected child requires the laboratory to have evidence of pre-test counselling by a genetics professional and written consent. For advice or assistance, please contact us on 1800 010 447.
Consent is managed by genetic counsellor.
Analysis of a gene panel for sequence abnormalities and deletions/duplications.
This test is provided by a Sonic Healthcare laboratory in Germany, Bioscientia.
For an updated list of genes included in the panel please click here.
Requesting the test
This test is usually requested by a cardiologist with experience in the genetic management of cardiac disease or a clinical geneticist.
2-5 mL blood in EDTA. Specimens may be collected by the requesting practitioner or at any Sonic Healthcare collection centre (see link below).
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
Please include a statement about family history (or absence of family history) of the disease in clinical details on referral form. If family history is present, please state relationship to patient.
This is the price for initial genetic testing of an affected person. Once a family's mutation is identified, targeted mutation analysis can be offered to family members; please contact Sonic Genetics on 1800 010 447 or at firstname.lastname@example.org regarding price and turn-around time.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.